Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized vehicle-controlled study of trifarotene cream in autosomal recessive lamellar ichthyosis
MOH_2020-01-23_008658Phase 2Completed
- Sponsor
- Mayne Pharma
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of trifarotene in autosomal recessive congenital ichthyosis (ARCI) (3 arms), sponsored by Mayne Pharma. Started Jan 2020; status: completed.
02
Drugs
trifarotene
03
Conditions
autosomal recessive congenital ichthyosis (ARCI)
Beyond the preview
Go deeper on MOH_2020-01-23_008658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-01-23_008658.